Leidos Biomedical Research Inc. awarded $121.5M for R&D by HHS/NIH

Contract Overview

Contract Amount: $121,524,563 ($121.5M)

Contractor: Leidos Biomedical Research Inc

Awarding Agency: Department of Health and Human Services

Start Date: 2020-08-31

End Date: 2024-08-30

Contract Duration: 1,460 days

Daily Burn Rate: $83.2K/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: COST PLUS FIXED FEE

Sector: R&D

Official Description: NIAID VRC

Place of Performance

Location: FREDERICK, FREDERICK County, MARYLAND, 21702

State: Maryland Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $121.5 million to LEIDOS BIOMEDICAL RESEARCH INC for work described as: NIAID VRC Key points: 1. Contract awarded to a single large business, Leidos Biomedical Research Inc. 2. Significant R&D spending in the Physical, Engineering, and Life Sciences sector. 3. Contract duration of 1460 days suggests a long-term project. 4. No small business participation indicated.

Value Assessment

Rating: fair

The contract type is Cost Plus Fixed Fee, which can lead to higher costs if not managed carefully. Benchmarking against similar R&D contracts is difficult without more specific details on the scope of work.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, suggesting a competitive bidding process. However, the specific awardee is Leidos Biomedical Research Inc., a large entity, and the impact on price discovery for this specific award is not detailed.

Taxpayer Impact: Taxpayer funds are being utilized for research and development, with the ultimate benefit depending on the success and applicability of the research outcomes.

Public Impact

Supports critical research and development efforts within the National Institutes of Health. Potential for advancements in physical, engineering, and life sciences. Funding allocated to a single large contractor may limit broader economic impact for smaller entities.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Positive Signals

Sector Analysis

This contract falls under the Research and Development in the Physical, Engineering, and Life Sciences sector. Spending in this area is crucial for innovation but can be highly variable and difficult to benchmark due to the specialized nature of the work.

Small Business Impact

The data indicates no small business participation in this contract. This suggests that the scope of work may have been better suited for larger organizations, or that outreach to small businesses was insufficient.

Oversight & Accountability

Oversight would typically be managed by the National Institutes of Health (NIH) through contract officers and technical monitors. Accountability for deliverables and cost management rests with Leidos Biomedical Research Inc. and the contracting agency.

Related Government Programs

Risk Flags

Tags

research-and-development-in-the-physical, department-of-health-and-human-services, md, delivery-order, 100m-plus

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $121.5 million to LEIDOS BIOMEDICAL RESEARCH INC. NIAID VRC

Who is the contractor on this award?

The obligated recipient is LEIDOS BIOMEDICAL RESEARCH INC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (National Institutes of Health).

What is the total obligated amount?

The obligated amount is $121.5 million.

What is the period of performance?

Start: 2020-08-31. End: 2024-08-30.

What specific research objectives does this $121.5M contract aim to achieve, and how will their success be measured?

The contract supports R&D in physical, engineering, and life sciences. Success metrics would likely involve achieving specific research milestones, publishing findings, or developing prototypes, as defined in the contract's statement of work. The NIH would monitor progress against these defined objectives to ensure value for taxpayer investment.

Given the Cost Plus Fixed Fee structure, what mechanisms are in place to mitigate potential cost overruns and ensure efficient use of funds?

Cost Plus Fixed Fee contracts require robust oversight. The NIH would likely employ detailed cost tracking, regular audits, and performance reviews to ensure Leidos Biomedical Research Inc. adheres to the budget. Fixed fee components incentivize completion, but careful monitoring of allowable costs is paramount.

How does this contract contribute to the broader scientific community and potential future innovations beyond the immediate research goals?

The R&D funded by this contract has the potential to yield significant scientific advancements. Dissemination of findings through publications and conferences, as well as potential spin-off technologies, can benefit the wider scientific community and spur further innovation, though the extent of this impact is not immediately quantifiable.

Industry Classification

NAICS: Professional, Scientific, and Technical ServicesScientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Product/Service Code: RESEARCH AND DEVELOPMENTN – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: COST PLUS FIXED FEE (U)

Evaluated Preference: NONE

Contractor Details

Parent Company: Leidos Holdings, Inc.

Address: 1050 BOYLES ST, FREDERICK, MD, 21702

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $125,780,282

Exercised Options: $125,780,282

Current Obligation: $121,524,563

Actual Outlays: $94,619,096

Subaward Activity

Number of Subawards: 42

Total Subaward Amount: $5,702,994

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: YES

Parent Contract

Parent Award PIID: 75N91019D00024

IDV Type: IDC

Timeline

Start Date: 2020-08-31

Current End Date: 2024-08-30

Potential End Date: 2024-08-30 00:00:00

Last Modified: 2024-08-16

More Contracts from Leidos Biomedical Research Inc

View all Leidos Biomedical Research Inc federal contracts →

Other Department of Health and Human Services Contracts

View all Department of Health and Human Services contracts →

Explore Related Government Spending